Innocoll Biotherapeutics

Innocoll Biotherapeutics company information, Employees & Contact Information

Updated May 2026

Quick answer

Innocoll Biotherapeutics is a Pharmaceutical Manufacturing company and founded in 1985. It has approximately 19 employees on record. Contact data was last refreshed in May 2026. Find Innocoll Biotherapeutics's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Innocoll is committed to improving patient care by confronting some of today’s most important healthcare challenges. Everyone at Innocoll is united by a common goal: to deliver healthcare solutions that make a difference in patients’ lives. We take pride in fostering a culture of collaboration, and we strive to be the best possible partners to the hospitals and doctors we support. Our current late-stage product pipeline, including XARACOLL (bupivacaine HCl) implant and POSIMIR (bupivacaine solution) for infiltration use, are focused on addressing patient needs for postsurgical pain management.

Company Details

Employees
19
Founded
1985
Address
210 Carnegie Center, 103,germany
Phone
(484) 406-5200
Email
bu****@****inc.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Princeton, New Jersey
Looking for a particular Innocoll Biotherapeutics employee's phone or email?

Innocoll Biotherapeutics Questions

News

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant - Business Wire

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant Business Wire

Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI) implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults - PR Newswire

Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI) implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults PR Newswire

Latham Advises Innocoll Biotherapeutics in US$125 Million Term Loan with Leading Biotech Investor Oaktree Capital - Latham & Watkins LLP

Latham Advises Innocoll Biotherapeutics in US$125 Million Term Loan with Leading Biotech Investor Oaktree Capital Latham & Watkins LLP

XaraColl Implant Approved for Postop Pain Following Hernia Repair - Medical Professionals Reference

XaraColl Implant Approved for Postop Pain Following Hernia Repair Medical Professionals Reference

Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer - Business Wire

Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer Business Wire

Innocoll stock slides 65 percent after FDA setback for pain treatment - FirstWord Pharma

Innocoll stock slides 65 percent after FDA setback for pain treatment FirstWord Pharma

Innocoll crushed after PhIII diabetic foot infection flop - Fierce Biotech

Innocoll crushed after PhIII diabetic foot infection flop Fierce Biotech

Anthony Galdi Appointed Chief Commercial Officer of Innocoll - BioSpace

Anthony Galdi Appointed Chief Commercial Officer of Innocoll BioSpace

FDA Approves XARACOLL® (bupivacaine HCl) Implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults - PR Newswire

FDA Approves XARACOLL® (bupivacaine HCl) Implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults PR Newswire

Innocoll Announces Successful Completion of Debt Refinancing - Business Wire

Innocoll Announces Successful Completion of Debt Refinancing Business Wire

Louis Pascarella Appointed Chief Executive Officer of Innocoll - Business Wire

Louis Pascarella Appointed Chief Executive Officer of Innocoll Business Wire

Here’s What Just Happened With Innocoll Holdings plc (NASDAQ:INNL) and NewLink Genetics Corporation (NASDAQ:NLNK) - marketexclusive.com

Here’s What Just Happened With Innocoll Holdings plc (NASDAQ:INNL) and NewLink Genetics Corporation (NASDAQ:NLNK) marketexclusive.com

Top Innocoll Biotherapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant